Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 301

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin

Open access
Pang, Nengzhi, Shi, Jingxuan, Qin, Le, Chen, Aiming, Tang, Yuou, Yang, Hainan, Huang, Yufeng, Wu, Qingde, Li, Xufeng, He, Bingjia, Li, Tianheng, Liang, Baoxia, Zhang, Jinglin, Cao, Bihui, Liu, Manting, Feng, Yunfei, Ye, Xiaodie, Chen, Xiaopei, Wang, Lu, Tian, Yu, Li, Hao, Li, Junping, Hu, Hong, He, Jingping, Hu, Yuling, Zhi, Cheng, Tang, Zhaoyang, Gong, Yibo, Xu, Fangting, Xu, Linfeng, Fan, Weijun, Zhao, Ming, Chen, Deji, Lian, Hui, Yang, Lili, Li, Peng, Zhang, Zhenfeng · 2021 · Journal of Hematology & Oncology

Abstract

Although chimeric antigen receptor (CAR)-engineered T cells have shown great success in the treatment of B cell malignancies, this strategy has limited efficacy in patients with solid tumors. In mouse CAR-T cells, IL-7 and CCL19 expression have been demonstrated to improve T cell infiltration and CAR-T cell survival in mouse tumors. Therefore, in the current study, we engineered human CAR-T cells to secrete human IL-7 and CCL19 (7 × 19) and found that these 7 × 19 CAR-T cells showed enhanced capacities of expansion and migration in vitro. Furthermore, 7 × 19 CAR-T cells showed superior tumor suppression ability compared to conventional CAR-T cells in xenografts of hepatocellular carcinoma (HCC) cell lines, primary HCC tissue samples and pancreatic carcinoma (PC) cell lines. We then initiated a phase 1 clinical trial in advanced HCC/PC/ovarian carcinoma (OC) patients with glypican-3 (GPC3) or mesothelin (MSLN) expression. In a patient with advanced HCC, anti-GPC3-7 × 19 CAR-T treatment resulted in complete tumor disappearance 30 days post intratumor injection. In a patient with advanced PC, anti-MSLN-7 × 19 CAR-T treatment resulted in almost complete tumor disappearance 240 days post-intravenous infusion. Our results demonstrated that the incorporation of 7 × 19 into CAR-T cells significantly enhanced the antitumor activity against human solid tumor. Trial registration: NCT03198546. Registered 26 June 2017, https://clinicaltrials.gov/ct2/show/NCT03198546?term=NCT03198546&draw=2&rank=1

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-021-01128-9

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 301

Metadata

Authors
Pang, N., Shi, J., Qin, L., Chen, A., Tang, Y., Yang, H., Huang, Y., Wu, Q., Li, X., He, B., Li, T., Liang, B., Zhang, J., Cao, B., Liu, M., Feng, Y., Ye, X., Chen, X., Wang, L., Tian, Y., Li, H., Li, J., Hu, H., He, J., Hu, Y., Zhi, C., Tang, Z., Gong, Y., Xu, F., Xu, L., Fan, W., Zhao, M., Chen, D., Lian, H., Yang, L., Li, P., & Zhang, Z.
Venue
Journal of Hematology & Oncology
Published
2021-07-29
Volume
14
Issue
1
Pages
118-118
ISSN
1756-8722 (ISSN-L)
OpenAlex
W3183435229
Cited by
301
References
11
FWCI
14.43
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. https://app.cochat.ai/papers/10.1186/s13045-021-01128-9
The paper
Pang, N., Shi, J., Qin, L., Chen, A., Tang, Y., Yang, H., Huang, Y., Wu, Q., Li, X., He, B., Li, T., Liang, B., Zhang, J., Cao, B., Liu, M., Feng, Y., Ye, X., Chen, X., Wang, L., . . . Zhang, Z. (2021). IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-021-01128-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.